Sarepta Therapeutics, Inc.
MX ˙ BMV ˙ US8036071004
SecurityMX:SRPT / Sarepta Therapeutics, Inc.
InstitutionUbs Asset Management Americas Inc
Latest Disclosed Ownership276,955 shares
Latest Disclosed Value $ 6,026,540
Ubs Asset Management Americas Inc reports 3.90% increase in ownership of SRPT / Sarepta Therapeutics, Inc.

On May 13, 2026 - Ubs Asset Management Americas Inc filed a 13F-HR form disclosing ownership of 276,955 shares of Sarepta Therapeutics, Inc. (MX:SRPT) valued at $6,026,540 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 13, 2026 disclosing 266,549 shares of Sarepta Therapeutics, Inc.. This represents a change in shares of 3.90% during the quarter.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-13 2026-03-31 13F SAREPTA THERAPEUTICS COM 803607100 276,955 10,406 3.90 6,027 5.06 0.0002
2026-02-13 2025-12-31 13F SAREPTA THERAPEUTICS COM 803607100 266,549 33,088 14.17 5,736 27.52 0.0012
2025-11-14 2025-09-30 13F SAREPTA THERAPEUTICS COM 803607100 233,461 -162,706 -41.07 4,499 -33.60 0.0010
2025-08-14 2025-06-30 13F SAREPTA THERAPEUTICS COM 803607100 396,167 -67,175 -14.50 6,774 -77.09 0.0014
2025-05-19 2025-03-31 13F SAREPTA THERAPEUTICS COM 803607100 463,342 164,041 54.81 29,570 -18.75 0.0076
2025-02-14 2024-12-31 13F SAREPTA THERAPEUTICS COM 803607100 299,301 31,098 11.59 36,392 8.65 0.0085
2024-11-14 2024-09-30 13F SAREPTA THERAPEUTICS COM 803607100 268,203 -33,278 -11.04 33,496 -29.68 0.0086
2024-08-14 2024-06-30 13F SAREPTA THERAPEUTICS COM 803607100 301,481 140,454 87.22 47,634 128.50 0.0137
2024-05-15 2024-03-31 13F SAREPTA THERAPEUTICS EQUITY US CM 803607100 161,027 15 0.01 20,847 34.27 0.0074
2024-02-14 2023-12-31 13F SAREPTA THERAPEUTICS EQUITY US CM 803607100 161,012 -170 -0.11 15,526 -20.53 0.0061
2023-11-13 2023-09-30 13F SAREPTA THERAPEUTICS EQUITY US CM 803607100 161,182 4,493 2.87 19,538 -9.53 0.0088
2023-08-11 2023-06-30 13F SAREPTA THERAPEUTICS EQUITY US CM 803607100 156,689 0 0.00 21,596 0.00 0.0105
2023-05-15 2023-03-31 13F SAREPTA THERAPEUTICS EQUITY US CM 803607100 156,689 35,368 29.15 21,596 37.38 0.0105
2023-02-14 2022-12-31 13F SAREPTA THERAPEUTICS EQUITY US CM 803607100 121,321 1,254 1.04 15,721 18.44 0.0082
2022-11-14 2022-09-30 13F SAREPTA THERAPEUTICS EQUITY US CM 803607100 120,067 -18,440 -13.31 13,272 27.84 0.0074
2022-08-12 2022-06-30 13F SAREPTA THERAPEUTICS EQUITY US CM 803607100 138,507 962 0.70 10,382 -3.38 0.0054
2022-05-16 2022-03-31 13F SAREPTA THERAPEUTICS EQUITY US CM 803607100 137,545 -27,201 -16.51 10,745 -27.57 0.0046
2022-02-14 2021-12-31 13F SAREPTA THERAPEUTICS EQUITY US CM 803607100 164,746 62,655 61.37 14,835 57.13 0.0057
2021-11-15 2021-09-30 13F SAREPTA THERAPEUTICS EQUITY US CM 803607100 102,091 -9,632 -8.62 9,441 8.70 0.0039
2021-08-16 2021-06-30 13F SAREPTA THERAPEUTICS EQUITY US CM 803607100 111,723 -93,319 -45.51 8,685 -43.16 0.0037
2021-05-14 2021-03-31 13F SAREPTA THERAPEUTICS EQUITY US CM 803607100 205,042 -201,513 -49.57 15,282 -77.95 0.0068
2021-03-01 2020-12-31 13F/A-1 SAREPTA THERAPEUTICS EQUITY US CM 803607100 406,555 10,676 2.70 69,314 24.68 0.0325
2021-02-17 2020-12-31 13F SAREPTA THERAPEUTICS EQUITY US CM 803607100 395,879 0 55,593 5.2434
2020-11-13 2020-09-30 13F SAREPTA THERAPEUTICS EQUITY US CM 803607100 395,879 340 0.09 55,593 -12.34 0.0299
2020-08-14 2020-06-30 13F SAREPTA THERAPEUTICS EQUITY US CM 803607100 395,539 -60,320 -13.23 63,421 42.22 0.0387
2020-05-15 2020-03-31 13F SAREPTA THERAPEUTICS EQUITY US CM 803607100 455,859 4,386 0.97 44,592 -23.46 0.0321
2020-02-14 2019-12-31 13F SAREPTA THERAPEUTICS EQUITY US CM 803607100 451,473 58,372 14.85 58,258 96.76 0.0357
2019-11-14 2019-09-30 13F SAREPTA THERAPEUTICS EQUITY US CM 803607100 393,101 96,536 32.55 29,608 -34.30 0.0199
2019-08-15 2019-06-30 13F SAREPTA THERAPEUTICS EQUITY US CM 803607100 296,565 42,263 16.62 45,063 48.67 0.0321
2019-05-14 2019-03-31 13F SAREPTA THERAPEUTICS EQUITY US CM 803607100 254,302 9,919 4.06 30,310 13.65 0.0225
2019-02-13 2018-12-31 13F SAREPTA THERAPEUTICS EQUITY US CM 803607100 244,383 21,262 9.53 26,670 -25.99 0.0230
2018-11-13 2018-09-30 13F SAREPTA THERAPEUTICS EQUITY US CM 803607100 223,121 223,121 36,036 0.0268
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.